Burden of rotavirus gastroenteritis in the Middle Eastern and North African pediatric population
1 BioMedCom Consultants inc., 1405 TransCanada Highway, Suite 310, Montreal, Quebec, H9P 2V9, Canada
2 Merck & Co, West Point, PA, 19486, USA
3 Lehigh University, Bethlehem, PA, 18015, USA
BMC Infectious Diseases 2011, 11:9 doi:10.1186/1471-2334-11-9Published: 7 January 2011
Rotavirus gastroenteritis (RVGE) is the most common cause of severe childhood diarrhea worldwide. Objectives were to estimate the burden of RVGE among children less than five years old in the Middle East (Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, Syria, UAE, Yemen), North Africa (Algeria, Egypt, Libya, Morocco, Tunisia) and Turkey.
A comprehensive literature search was conducted in major databases on the epidemiology and burden of rotavirus among children less than five years old between 1999 and 2009. Data from each country was extracted and compared.
The search identified 43 studies. RVGE was identified in 16-61% of all cases of acute gastroenteritis, with a peak in the winter. RVGE-related hospitalization rates ranged from 14% to 45%, compared to 14%-28% for non-RVGE. Annually, RVGE caused up to 112 fatalities per 100,000 in certain countries in the region. Hospitalization costs ranged from $1.8 to $4.6 million annually, depending on the country. The most recent literature available showed that G1P was the most prevalent genotype combination in 8 countries (range 23%-56%). G2P was most prevalent in 4 countries (26%-48%). G9P and G4P were also frequently detected.
RVGE is a common disease associated with significant morbidity, mortality, and economic burden. Given the variety and diverse rotavirus types in the region, use of a vaccine with broad and consistent serotype coverage would be important to help decrease the burden of RVGE in the Middle East and North Africa.